Stanley Abel
Direttore/Membro del Consiglio presso ADYNXX, INC.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Rick Orr | M | - |
SiteOne Therapeutics, Inc.
 SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT.
Cerexa, Inc.
 Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA.
Corthera, Inc.
 Corthera, Inc. Pharmaceuticals: MajorHealth Technology Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA. | 14 anni |
| Julien Mamet | M | - | 17 anni | |
| Dennis Podlesak | M | 66 |
Peninsula Pharmaceuticals, Inc.
 Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA.
Corthera, Inc.
Corthera, Inc. Pharmaceuticals: MajorHealth Technology Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA. | 3 anni |
| Eckard Weber | M | 73 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA.
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | - |
| John Mulcahy | M | - |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 14 anni |
| Erin Fleming | M | - |
ProJenX, Inc.
 ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | - |
| Matthew Ruth | M | - | 5 anni | |
| George Miljanich | M | - |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 14 anni |
| Valerie Estess | F | - |
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | - |
| Justin Du Bois | M | - |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 14 anni |
| Dina Gonzalez | F | - | 14 anni | |
| William Martin | M | - | 12 anni | |
| Tim Layton | M | - |
The Montana Bioscience Alliance
 The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | 7 anni |
| Hynek Wichterle | M | - |
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | - |
| Kurt Toenjes | M | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
| Kathy Jutila | F | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
| Robert Goodwin | M | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
| Ken Fichtler | M | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
| Richard Bridges | M | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
| Pamela Sager | F | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
| Jay T. Evans | M | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | 7 anni |
| Eric Heil | M | - |
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | - |
| Mark Jutila | M | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
| Teresa Gunn | F | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
| John Prufeta | M | - |
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | - |
| Chad DeLong | M | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
| John Delaney | M | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
| David Yeomans | M | - |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 14 anni |
| Sandip Biswal | M | - |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 14 anni |
| Scott Braunstein | M | 60 |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 6 anni |
| Will Price | M | - |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 9 anni |
| Joe Fanguy | M | - |
The Montana Bioscience Alliance
The Montana Bioscience Alliance Miscellaneous Commercial ServicesCommercial Services The Montana Bioscience Alliance serves as a hub for Montana’s biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize grow and sustain globally competitive bioscience companies. It Serve as the interface between the life sciences cluster and state government to help implement and improve the state’s life sciences cluster development strategy. The company was founded in 2004 and is headquartered in Billings, MT. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Lowell E. Sears | M | 73 |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT.
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | 3 anni |
| Dirk Thye | M | 54 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | 4 anni |
| Keith Katkin | M | 52 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | 2 anni |
| Georgina H. Kilfoil | F | 55 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | 1 anni |
| Patrick Heron | M | 53 |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | 2 anni |
| Arthur E. Colvin | M | - |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | - |
| Joseph Zakrzewski | M | 60 |
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | 6 anni |
| Pierre Legault | M | 63 | - | |
| Christopher Lowe | M | 56 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | 1 anni |
| David Ian Johnson | M | 66 | - | |
| Ursula Fritsch | M | 64 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | 2 anni |
| Gregory Flesher | M | 54 | 2 anni | |
| Colin Hislop | M | 66 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | 1 anni |
| George Harrison Talbot | M | 76 |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | 1 anni |
| Donald C. Manning | M | 65 | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 47 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Stanley Abel
- Contatti personali